Going beyond the numbers – a call to redefine polypharmacy
The adverse events profile of anti-IGF-1R monoclonal antibodies in cancer therapy
Incidence and relative risk of hepatic toxicity in patients treated with anti-angiogenic tyrosine kinase inhibitors for malignancy
Proposal for new European pharmaceutical legislation to permit access to custom-made anti-sense oligonucleotide medicinal products
Urinary kidney biomarkers for early detection of nephrotoxicity in clinical drug development
Metabolic disturbances and renal stone promotion on treatment with topiramate: a systematic review
The H3 antagonist ABT-288 is tolerated at significantly higher exposures in subjects with schizophrenia than in healthy volunteers
Melatonin for sedative withdrawal in older patients with primary insomnia: a randomized double-blind placebo-controlled trial
Pharmacokinetics and pharmacodynamics of liposomal mifamurtide in adult volunteers with mild or moderate renal impairment
Pharmacokinetics and pharmacodynamics of liposomal mifamurtide in adult volunteers with mild or moderate hepatic impairment
The absolute bioavailability of racemic ketamine from a novel sublingual formulation
Human disposition, metabolism and excretion of etamicastat, a reversible, peripherally selective dopamine β-hydroxylase inhibitor
Population pharmacokinetics of nefopam in elderly, with or without renal impairment, and its link to treatment response
Cytochrome P450 3A and P-glycoprotein drug–drug interactions with voclosporin
Population pharmacokinetics and Bayesian estimation of tacrolimus exposure in paediatric liver transplant recipients
Effectiveness of newspaper advertising for patient recruitment into a clinical trial
Is polypharmacy always hazardous? A retrospective cohort analysis using linked electronic health records from primary and secondary care
Methylphenidate and pregnancy
Response to Damkier
Clinical relevance of the (S)-citalopram–omeprazole interaction in geriatric patients
The licence for a custom-made medicinal product is an adaptive licence
Ron Mann
Pharmacogenomics: challenges and opportunities in therapeutic implementation